MorphoSys AG / Sloning BioTechnology GmbH / Novel Antibody Platform Ylanthia MorphoSys AG / Frankfurt Stock Exchange / /
Country
Germany / / /
Event
Company Listing Change / /
Facility
Ylanthia library / Fab library / /
IndustryTerm
pharmaceutical industry / treatment of cancer / human healthcare / pharmaceutical partners / healthcare products / manufacturing / antibody products / antibody library technology / antibody technology / /
MedicalCondition
Alzheimer’s disease / cancer / rheumatoid arthritis / /
Person
Marlies Sproll / / /
Position
Chief Scientific Officer / Claudia Gutjahr-Löser Head of Corporate Communications / leader / Alexandra Goller Specialist Corporate Communications / Director Corporate Communications & IR Tel / /
Product
Slonomics / Ylanthia / HuCAL / /
Technology
antibody technology / antibodies / antibody library technology / Slonomics technology / drug development / optimized using MorphoSys's proprietary Slonomics technology / /
Media Release Martinsried/Munich, Germany, 10 May 2013 MorphoSys Announces First Scientific Publication on Novel Antibody Platform Ylanthia MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) announced today that a